Alterity Therapeutics Ltd Stock Price, News & Analysis

Alterity Therapeutics (NASDAQ: ATHE) has announced the completion of the last patient visit in its ATH434-202 Phase 2 open-label trial for Multiple System Atrophy (MSA). The study aims to evaluate the safety, efficacy, and target engagement of ATH434, a disease-modifying drug candidate for neurodegenerative diseases, specifically in patients with advanced MSA.

Following positive results from their previous randomized, double-blind Phase 2 trial, this open-label study focuses on a population with advanced-stage illness. The company expects to report topline data by mid-year 2025. CEO David Stamler emphasized that the data will help guide their development program, noting the differences between this study and the double-blind trial.

Alterity Therapeutics (NASDAQ: ATHE) has secured binding commitments for a A$40.0 million capital raise through a two-tranche placement of ordinary shares to institutional and sophisticated investors. The placement was conducted at A$0.011 per share, an 8.3% discount to the last closing price, with one free attaching option for every three new shares issued.

The funding will primarily support the advancement of ATH434, their lead compound for neurodegenerative diseases, which recently showed significant results in Multiple System Atrophy (MSA) treatment. The Phase 2 clinical trial demonstrated a 48% slowing of clinical progression at the 50mg dose and favorable safety profile.

The placement consists of a A$12.8 million Tranche One (1.2 billion shares) and a A$27.2 million Tranche Two (2.5 billion shares), with the latter requiring shareholder approval at an Extraordinary General Meeting expected in March 2025.

Alterity Therapeutics announced positive topline results from their ATH434-201 Phase 2 clinical trial for treating early-stage multiple system atrophy (MSA). The trial demonstrated significant clinical benefits, with the 50mg dose showing a 48% slowing of clinical progression (p=0.03) and the 75mg dose showing a 29% slowing at Week 52 compared to placebo.

Key findings include:

• Reduced iron accumulation in MSA-affected brain regions
• Trends in preservation of brain volume
• Improved motor performance on the Parkinson's Plus rating scale
• Favorable safety profile with no serious adverse events related to ATH434

The study enrolled 77 adults across 23 sites in six countries, with participants randomly assigned to receive either 50mg, 75mg, or placebo. The 50mg dose demonstrated the most promising results, showing statistically significant improvement on the modified UMSARS Part I, a key clinical endpoint for FDA approval.

Alterity Therapeutics (NASDAQ: ATHE) has reported significant progress in Q2 FY25, particularly with its lead asset ATH434. The company completed its ATH434-201 Phase 2 clinical trial in early-stage Multiple System Atrophy (MSA) in November 2024, with topline data expected by early February 2025.

Positive interim data from the ATH434-202 Phase 2 trial in advanced MSA showed promising results, with 30% of participants demonstrating stable or improved clinical outcomes. The trial suggests potential disease-modifying effects, with stabilization of brain iron and volume after 12 months of treatment.

Multiple presentations and publications during the quarter highlighted ATH434's neuroprotective qualities and mechanism of action in treating various neurodegenerative conditions, including MSA, Parkinson's disease, and Friedreich's Ataxia. The company's cash position as of December 31, 2024, stood at A$4.54M, with quarterly operating cash outflows of A$5.06M.

Alterity Therapeutics (NASDAQ: ATHE) has issued a shareholder letter highlighting significant progress in 2024 and upcoming milestones for 2025. The company completed a 12-month, double-blind Phase 2 clinical trial of ATH434 in early-stage Multiple System Atrophy (MSA), with topline data expected in late January or early February.

Preliminary results from their open-label biomarker study in advanced MSA patients showed stable or improved clinical measures after 6-months of ATH434 treatment. The study demonstrated stable iron levels and brain volumes in clinical responders, along with reduced neuronal injury compared to untreated patients.

The company also presented preclinical data showing ATH434's potential in a primate model of Parkinson's disease. Their bioMUSE Natural History study, in collaboration with Vanderbilt University Medical Center, led to developing a novel imaging biomarker for assessing brain volume in MSA-affected regions.

Alterity Therapeutics has announced the completion of the last patient visit in its ATH434-201 Phase 2 clinical trial for early-stage multiple system atrophy (MSA). The trial, which is a randomized, double-blind, placebo-controlled study, evaluates ATH434, a disease-modifying drug candidate targeting alpha-synuclein and iron in Parkinsonian disorders.

The company expects to report topline results in late January or early February 2025. This milestone marks the beginning of the final phase, which includes database cleaning and locking before the release of results. The study has garnered significant interest from clinical sites, doctors, and patients globally in the pursuit of a treatment that could potentially slow MSA progression.

Alterity Therapeutics (NASDAQ: ATHE) has appointed Abby Macnish Niven as Company Secretary, following her recent appointment as Chief Financial Officer on September 30, 2024. She succeeds Phillip Hains in the secretary role effective November 18, 2024. Macnish Niven brings extensive experience in private wealth management from ANZ, UBS, and Ord Minett, and consults on governance, finance, and corporate structure. She holds Bachelor degrees in Commerce and Science from the University of Western Australia and is a Chartered Finance Analyst. In this role, she will be responsible for communications between Alterity and ASX.

Alterity Therapeutics presented data from their bioMUSE natural history study at the 35th International Symposium on the Autonomic Nervous System. The presentation focused on tracking Multiple System Atrophy (MSA) progression using advanced neuroimaging techniques. The study introduced the MSA Atrophy Index (MSA-AI), a composite marker derived from specific brain regions to assess disease progression.

Using machine learning tools and state-of-the-art technology beyond traditional MRI methods, researchers observed significant brain volume reductions over 12 months that correlated with clinical worsening. These methods aim to enhance understanding of MSA progression and support the evaluation of disease-modifying therapies.

Alterity Therapeutics (NASDAQ: ATHE) announced a new publication in Metallomics journal highlighting ATH434's unique mechanism as an iron chaperone for treating neurodegenerative diseases. The study demonstrates how ATH434 targets excess reactive iron, which is implicated in conditions like Friedreich's Ataxia, Parkinson's disease, and multiple system atrophy (MSA). Unlike traditional iron chelators, ATH434 shows lower affinity for ferric iron and reversible binding, allowing it to redistribute excess reactive iron without disrupting normal iron functions or generating harmful free radicals.